vs

Side-by-side financial comparison of Organogenesis Holdings Inc. (ORGO) and Verisign (VRSN). Click either name above to swap in a different company.

Verisign is the larger business by last-quarter revenue ($425.3M vs $225.6M, roughly 1.9× Organogenesis Holdings Inc.). Verisign runs the higher net margin — 48.5% vs 19.4%, a 29.1% gap on every dollar of revenue. On growth, Organogenesis Holdings Inc. posted the faster year-over-year revenue change (78.1% vs 7.6%). Verisign produced more free cash flow last quarter ($285.1M vs $34.8M). Over the past eight quarters, Organogenesis Holdings Inc.'s revenue compounded faster (43.2% CAGR vs 5.2%).

Organogenesis Holdings Inc. is a leading regenerative medicine firm specializing in developing and manufacturing advanced therapeutic products for wound care, surgical repair, sports medicine, and dermatology. It serves healthcare providers and patients primarily in the U.S. and select international markets, offering clinically validated solutions for unmet medical needs.

Verisign, Inc. is an American company based in Reston, Virginia, that operates a diverse array of network infrastructure, including two of the Internet's thirteen root nameservers, the authoritative registry for the .com, .net, and .name generic top-level domains and the .cc country-code top-level domains, and the back-end systems for the .jobs and .edu sponsored top-level domains.

ORGO vs VRSN — Head-to-Head

Bigger by revenue
VRSN
VRSN
1.9× larger
VRSN
$425.3M
$225.6M
ORGO
Growing faster (revenue YoY)
ORGO
ORGO
+70.6% gap
ORGO
78.1%
7.6%
VRSN
Higher net margin
VRSN
VRSN
29.1% more per $
VRSN
48.5%
19.4%
ORGO
More free cash flow
VRSN
VRSN
$250.3M more FCF
VRSN
$285.1M
$34.8M
ORGO
Faster 2-yr revenue CAGR
ORGO
ORGO
Annualised
ORGO
43.2%
5.2%
VRSN

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ORGO
ORGO
VRSN
VRSN
Revenue
$225.6M
$425.3M
Net Profit
$43.7M
$206.2M
Gross Margin
88.5%
Operating Margin
28.1%
67.0%
Net Margin
19.4%
48.5%
Revenue YoY
78.1%
7.6%
Net Profit YoY
469.5%
7.7%
EPS (diluted)
$0.31

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ORGO
ORGO
VRSN
VRSN
Q4 25
$225.6M
$425.3M
Q3 25
$150.9M
$419.1M
Q2 25
$101.0M
$409.9M
Q1 25
$86.7M
$402.3M
Q4 24
$126.7M
$395.4M
Q3 24
$115.2M
$390.6M
Q2 24
$130.2M
$387.1M
Q1 24
$110.0M
$384.3M
Net Profit
ORGO
ORGO
VRSN
VRSN
Q4 25
$43.7M
$206.2M
Q3 25
$21.6M
$212.8M
Q2 25
$-9.4M
$207.4M
Q1 25
$-18.8M
$199.3M
Q4 24
$7.7M
$191.5M
Q3 24
$12.3M
$201.3M
Q2 24
$-17.0M
$198.8M
Q1 24
$-2.1M
$194.1M
Gross Margin
ORGO
ORGO
VRSN
VRSN
Q4 25
88.5%
Q3 25
88.4%
Q2 25
88.0%
Q1 25
72.6%
87.7%
Q4 24
75.5%
87.8%
Q3 24
76.7%
88.0%
Q2 24
77.6%
87.8%
Q1 24
73.9%
87.2%
Operating Margin
ORGO
ORGO
VRSN
VRSN
Q4 25
28.1%
67.0%
Q3 25
13.7%
67.8%
Q2 25
-12.5%
68.5%
Q1 25
-30.9%
67.4%
Q4 24
8.1%
66.7%
Q3 24
5.4%
68.9%
Q2 24
-10.7%
68.8%
Q1 24
-3.5%
67.4%
Net Margin
ORGO
ORGO
VRSN
VRSN
Q4 25
19.4%
48.5%
Q3 25
14.3%
50.8%
Q2 25
-9.3%
50.6%
Q1 25
-21.7%
49.5%
Q4 24
6.1%
48.4%
Q3 24
10.7%
51.5%
Q2 24
-13.1%
51.4%
Q1 24
-1.9%
50.5%
EPS (diluted)
ORGO
ORGO
VRSN
VRSN
Q4 25
$0.31
Q3 25
$0.11
Q2 25
$-0.10
Q1 25
$-0.17
Q4 24
$0.05
Q3 24
$0.09
Q2 24
$-0.13
Q1 24
$-0.02

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ORGO
ORGO
VRSN
VRSN
Cash + ST InvestmentsLiquidity on hand
$93.7M
$580.5M
Total DebtLower is stronger
Stockholders' EquityBook value
$300.1M
$-2.2B
Total Assets
$598.7M
$1.3B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ORGO
ORGO
VRSN
VRSN
Q4 25
$93.7M
$580.5M
Q3 25
$63.7M
$617.7M
Q2 25
$73.1M
$593.8M
Q1 25
$110.0M
$648.5M
Q4 24
$135.6M
$599.9M
Q3 24
$94.3M
$644.9M
Q2 24
$89.9M
$689.9M
Q1 24
$88.6M
$924.7M
Total Debt
ORGO
ORGO
VRSN
VRSN
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
$62.3M
Q2 24
$63.8M
Q1 24
$65.2M
Stockholders' Equity
ORGO
ORGO
VRSN
VRSN
Q4 25
$300.1M
$-2.2B
Q3 25
$255.1M
$-2.1B
Q2 25
$233.2M
$-2.0B
Q1 25
$242.9M
$-2.0B
Q4 24
$262.9M
$-2.0B
Q3 24
$278.5M
$-1.9B
Q2 24
$263.5M
$-1.8B
Q1 24
$278.0M
$-1.6B
Total Assets
ORGO
ORGO
VRSN
VRSN
Q4 25
$598.7M
$1.3B
Q3 25
$509.8M
$1.4B
Q2 25
$461.1M
$1.4B
Q1 25
$467.4M
$1.4B
Q4 24
$497.9M
$1.4B
Q3 24
$446.3M
$1.5B
Q2 24
$443.2M
$1.5B
Q1 24
$458.5M
$1.7B
Debt / Equity
ORGO
ORGO
VRSN
VRSN
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
0.22×
Q2 24
0.24×
Q1 24
0.23×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ORGO
ORGO
VRSN
VRSN
Operating Cash FlowLast quarter
$39.4M
$289.6M
Free Cash FlowOCF − Capex
$34.8M
$285.1M
FCF MarginFCF / Revenue
15.4%
67.0%
Capex IntensityCapex / Revenue
2.1%
1.1%
Cash ConversionOCF / Net Profit
0.90×
1.40×
TTM Free Cash FlowTrailing 4 quarters
$-24.5M
$1.1B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ORGO
ORGO
VRSN
VRSN
Q4 25
$39.4M
$289.6M
Q3 25
$3.1M
$307.7M
Q2 25
$-32.9M
$202.5M
Q1 25
$-19.9M
$291.3M
Q4 24
$10.9M
$231.5M
Q3 24
$8.7M
$253.4M
Q2 24
$4.7M
$160.4M
Q1 24
$-10.2M
$257.3M
Free Cash Flow
ORGO
ORGO
VRSN
VRSN
Q4 25
$34.8M
$285.1M
Q3 25
$844.0K
$303.0M
Q2 25
$-36.5M
$194.7M
Q1 25
$-23.6M
$285.5M
Q4 24
$7.6M
$222.0M
Q3 24
$6.1M
$247.8M
Q2 24
$2.9M
$151.2M
Q1 24
$-12.4M
$253.5M
FCF Margin
ORGO
ORGO
VRSN
VRSN
Q4 25
15.4%
67.0%
Q3 25
0.6%
72.3%
Q2 25
-36.1%
47.5%
Q1 25
-27.2%
71.0%
Q4 24
6.0%
56.1%
Q3 24
5.3%
63.4%
Q2 24
2.2%
39.1%
Q1 24
-11.3%
66.0%
Capex Intensity
ORGO
ORGO
VRSN
VRSN
Q4 25
2.1%
1.1%
Q3 25
1.5%
1.1%
Q2 25
3.6%
1.9%
Q1 25
4.2%
1.4%
Q4 24
2.7%
2.4%
Q3 24
2.2%
1.4%
Q2 24
1.4%
2.4%
Q1 24
2.0%
1.0%
Cash Conversion
ORGO
ORGO
VRSN
VRSN
Q4 25
0.90×
1.40×
Q3 25
0.14×
1.45×
Q2 25
0.98×
Q1 25
1.46×
Q4 24
1.43×
1.21×
Q3 24
0.71×
1.26×
Q2 24
0.81×
Q1 24
1.33×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons